Clinical trials: EGFR Mutated Non-small Cell Lung Cancer Patients
Non-Small-Cell Lung Cancer
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R…
- Trial name
- NCT06827145
- Testing
- Vebreltinib, Osimertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, China
Non-small Cell Lung Cancer
Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC
This is a prospective, single-arm, open-label, interventional clinical study, aimed at exploring the efficacy and safety of sequential Envafolimab immunotherapy after patients with ctDNA EGFR mutation clearance and achieved…
- Trial name
- NCT05534113
- Testing
- Almonertinib Envafolimab
- Volunteers
- 38 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
This randomized phase II trial studies how well erlotinib hydrochloride (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor…
- Conditions
- EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01532089
- Testing
- Bevacizumab, Erlotinib, Erlotinib Hydrochloride
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- Academic and Community Cancer Research United
Non-Small-Cell Lung Cancer
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
This is a single-arm, exploratory phase Ib/II study with a seamless design to evaluate the safety and efficacy of Vebreltinib combined with furmonertinib as first-line treatment in patients with locally advanced or metastatic…
- Trial name
- DUAL-THRUST (NCT07655622)
- Testing
- Vebreltinib, Furmonertinib 80mg
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Non-small-cell Lung Cancer
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of combination of gefitinib and doublet chemotherapy or antiangiogenesis in advanced non-small cell lung cancer patients with EGFR activating…
- Trial name
- NCT02930954
- Testing
- Gefitinib, pemetrexed or gemcitabine plus carboplatin,, bevacizumab
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Caicun Zhou
Non-Small-Cell Lung Carcinoma
Anticancer Activity of Nicotinamide on Lung Cancer
Nicotinamide is an inhibitor of human sirtuins (HDAC III), and is found to re-activate epigenetically silenced tumor suppressors, RUNX3 (runt-related gene 3) and others, in cancer cells.
- Trial name
- NCT02416739
- Testing
- Nicotinamide
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Il Yeong Park, Ph.D.
Non-small Cell Lung Cancer, Effects of Chemotherapy
Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
In the National Comprehensive Cancer Network (NCCN) guideline for NSCLC, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is recommended as the third-line treatment for EGFR gene mutation negative NSCLC…
- Trial name
- NCT01749072
- Testing
- Gefitinib group, Vinorelbine, Ifosfamide, Mesna
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Non-Small Cell Lung Cancer, Brain Metastases
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
1. Compare the effect and safety of gefitinib alone with gefitinib plus concomitant WBRT(whole-brain radiotherapy ) in treatment of NSCLC patients harboring an EGFR mutation with multiple BM. 2.
- Conditions
- Non-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
- Trial name
- EGFR (NCT02338011)
- Testing
- Gefitinib, WBRT
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic EGFR mutated non-small…
- Trial name
- NCT06279728
- Testing
- Datopotamab deruxtecan
- Where
- 14 sites in United States
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
The purpose of this study is to investigate whether high-dose icotinib treatment beyond disease progression is beneficial for NSCLC patients who have EGFR mutation and who have responded to EGFR TKI.
- Trial name
- NCT02960607
- Testing
- Icotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00903292
- Testing
- erlotinib (Tarceva), pemetrexed (Alimta)
- Where
- Taiwan
- Volunteers
- 52 people
- Sponsor
- National Cheng-Kung University Hospital
Non-Small Cell Lung Cancer
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
- Trial name
- NCT05007938
- Testing
- Icotinib, Befotertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced Non-small Cell Lung Cancer
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
This is a Phase I/II, multi-center, open-label study, composed with a Phase I part (dose-escalation phase) followed by a Phase II part (expansion phase).
- Trial name
- NCT02108964
- Testing
- EGF816
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer Stage II
Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment
A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI…
- Trial name
- NCT04970043
- Testing
- Camrelizumab+ pemetrexed + platinum
- Volunteers
- 58 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to access the effect and safety of radiotherapy combined whth Iressa for patients with locally advanced non-small cell lung cancer with harboring active EGFR mutations.
- Trial name
- NCT01391260
- Testing
- Gefitinib
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- ZhuGuangYing
NSCLC
Conmana Combined With Thalidomide to Treat NSCLC
Our study the NSCLC harbors EGFR-mutation with Conmana combined with thalidomide as first-line treatment, is expected to improve further EGFR-Tyrosine kinase inhibitors (TKI) response rate (ORR), prolong time to progression…
- Trial name
- NCT02778893
- Testing
- Conmana, Thalidomide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Henan Provincial People's Hospital
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
To assess the efficacy and safety of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
- Trial name
- FLAURA (NCT02296125)
- Testing
- Erlotinib 150/100 mg, Gefitinib 250 mg
- Where
- 170 sites in United States, Australia and 28 more
- Volunteers
- 674 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs.
- Trial name
- PANORAMRETRO (NCT03721289)
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 463 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent, No EGFR Activating Mutation
Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
In France, lung cancer is the leading cause of death induced by cancer. Therapeutic advances have been made in therapy of unresectable non-small cell lung cancer (NSCLC) with tyrosine kinase receptor inhibitors blocking the…
- Trial name
- FLT-THERA (NCT02069418)
- Testing
- 18F-FLT-TEP, 18F-FDG-TEP
- Where
- 8 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Angers
Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have…
- Conditions
- Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer NSCLC, Non Small Cell Lung Carcinoma
- Trial name
- OMAE (NCT07563205)
- Where
- 16 sites in France
- Volunteers
- 100 people
- Sponsor
- GFPC Investigation